Skip to Main Content

Author Details

Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
2006
140
45
PMIDPaper TitleJournal TitlePublished Year
37428992Reply to R. Freitas-Junior et al.JCO Glob Oncol2023
37793216Clinical and genomic characterisation of early-onset pancreatic cancer.Eur J Cancer2023
37704212Early-Stage Breast Cancer Detection in Breast Milk.Cancer Discov2023
37509274Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.Cancers (Basel)2023
37641393Precision cancer medicine: Concepts, current practice, and future developments.J Intern Med2023
37572657A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.Med2023
37602420Challenges and opportunities in building a health economic framework for personalized medicine in oncology.Per Med2023
36989964Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.Oral Oncol2023
37469678Complete Response to Immunotherapy in a Patient with <i>MUTYH</i>-Associated Polyposis and Gastric Cancer: A Case Report.Case Rep Oncol2023
37003083Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.Cancer Treat Rev2023
37097008Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.Mol Oncol2023
34593528High <i>FGFR1-4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.Clin Cancer Res2022
35425960Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.Cancer Res2022
36613564A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.Int J Mol Sci2022
35939770An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.JCO Precis Oncol2022
36209603Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias".Cancer Treat Rev2022
36071033High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.Nat Commun2022
36097219RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancer.Nat Med2022
36353186Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario.J Mark Access Health Policy2022
36351212Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil.JCO Glob Oncol2022
36055302Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?Lancet Oncol2022
35912589Biologics in rectal cancer.Expert Opin Biol Ther2022
36376284Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.Nat Commun2022
35042699ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.Clin Cancer Res2022
35179562PCIG: a web-based application to explore immune-genomics interactions across cancer types.Bioinformatics2022
35144055Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis.Cancer Treat Rev2022
32562197Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients.Clin Transl Oncol2021
33672114Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy.Cancers (Basel)2021
33838532Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.ESMO Open2021
33723394PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.Br J Cancer2021
33497314A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.Radiology2021
34385069Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.Eur J Cancer2021
34383598Fluorouracil Bolus Use in Infusional Regimens Among Oncologists-A Survey by Brazilian Group of Gastrointestinal Tumors.JCO Glob Oncol2021
34735818Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean.Lancet Oncol2021
34378095Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.Ann Hematol2021
34725384Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort.Sci Rep2021
34426441Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer.Clin Cancer Res2021
34741675The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.Curr Treat Options Oncol2021
33992745Genomic testing for targeted oncology drugs: hopes against hype.Ann Oncol2021
34099718The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.NPJ Breast Cancer2021
34109281Is It Time to Implement Adjuvant Targeted Therapy in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer?JCO Precis Oncol2021
33434066Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil.JCO Glob Oncol2021
32909055Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis.Eur Radiol2021
32220884Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.Clin Cancer Res2020
31757877Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.Clin Cancer Res2020
31744639Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].Gynecol Oncol2020
31916017Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.Clin Transl Oncol2020
33120239Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer.Eur J Radiol2020
32853681Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.Ann Oncol2020
32759276Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.Sci Transl Med2020
  • 1 - 50 of 140

Recommended Authors

Walid K Chatila
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 10
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 1
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 3
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 6
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 1
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 10
Stephen Welch
Victoria Hospital
Career Start Year 2007
Number of shared co-authors 3
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 2
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 8
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 6
Celina Ang
Tisch Cancer Institute, Mount Sinai Hospital
Career Start Year 2005
Number of shared co-authors 0
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 29
Jeeyun Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2003
Number of shared co-authors 9
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 8
Jonathan R Dry
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 18
Simon Kreutzfeldt
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2002
Number of shared co-authors 17
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 3
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 3
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 17
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 5
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 8
Joon Oh Park
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 1997
Number of shared co-authors 1
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 13
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 10
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 12
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 15
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 5
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 4

Collaborators

Jordi Rodon
The University of Texas MD Anderson Cancer Center
Co-authored papers 21
Justin Guinney
University of Washington
Co-authored papers 12
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 7
Nuria Lopez-Bigas
Universitat Pompeu Fabra
Co-authored papers 7
Abel Gonzalez-Perez
Universitat Pompeu Fabra
Co-authored papers 5
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 5
David Tamborero
Universitat Pompeu Fabra
Co-authored papers 5
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 5
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 5
José Baselga
Co-authored papers 4
Brian M Bot
Co-authored papers 4
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 4
Mauro Delorenzi
Co-authored papers 3
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Louis Vermeulen
Oncode Institute
Co-authored papers 3
Stephen H Friend
University of Oxford
Co-authored papers 3
Adam A Margolin
Icahn School of Medicine
Co-authored papers 3
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Isabel T Rubio
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Co-authored papers 2
Mark Lawler
Queens University Belfast Belfast
Co-authored papers 2
Kilannin Krysiak
Washington University School of Medicine
Co-authored papers 2
Anthony J Iafrate
Massachusetts General Hospital
Co-authored papers 2
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 2
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Steven R Alberts
Mayo Clinic
Co-authored papers 2
Joan Albanell
Hospital del Mar Research Institute
Co-authored papers 2
Malachi Griffith
Washington University
Co-authored papers 2
Damian T Rieke
German Cancer Consortium and German Cancer Research Center
Co-authored papers 2
Obi L Griffith
Washington University
Co-authored papers 2
Release 1.2